Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal recessive non-syndromic intellectual disability in which the cause of the disease is a mutation in the TNIK gene.
Features include always present findings: Intellectual disability; and sometimes findings: Exaggerated startle response, Emotional lability, and Attention deficit hyperactivity disorder. 5 total HPO annotations.
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:58 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Exaggerated startle response, Delayed speech and language development, Emotional lability |
TNIK function has not been fully characterized.
Intellectual disability, autosomal recessive 54 is associated with mutations in the TNIK gene on chromosome 3.
Genetic testing for TNIK is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for intellectual disability, autosomal recessive 54 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature.
No clinical trials have been registered for intellectual disability, autosomal recessive 54.
129 publications have been identified in PubMed for intellectual disability, autosomal recessive 54. Research spans Epidemiology / Natural History (37%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 48 | 37% |
Research summaries | 31 | 24% |
Laboratory research | 24 | 19% |
Clinical study results | 10 | 8% |
Testing and diagnosis research | 7 | 5% |
Patient case studies | 5 | 4% |
Other research | 4 | 3% |
Balestrini S (2026). [PMID: 41137852](https://pubmed.ncbi.nlm.nih.gov/41137852/). *Epilepsia*. [Epidemiology / Natural History]
Miller JL (2026). [PMID: 41482637](https://pubmed.ncbi.nlm.nih.gov/41482637/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Rotulo GA (2026). [PMID: 41390316](https://pubmed.ncbi.nlm.nih.gov/41390316/). *Pediatr Neonatol*. [Review / Meta-Analysis]
Peyre H (2026). [PMID: 42014468](https://pubmed.ncbi.nlm.nih.gov/42014468/). *Mol Psychiatry*. [Epidemiology / Natural History]
Lee J (2026). [PMID: 41762932](https://pubmed.ncbi.nlm.nih.gov/41762932/). *Res Dev Disabil*. [Epidemiology / Natural History]
Chaabouni M (2026). [PMID: 41854122](https://pubmed.ncbi.nlm.nih.gov/41854122/). *Clin Genet*. [Basic Science / Preclinical]
Feng Z (2026). [PMID: 41795174](https://pubmed.ncbi.nlm.nih.gov/41795174/). *Am J Med Genet A*. [Diagnostic / Biomarker]
Pan X (2026). [PMID: 41764152](https://pubmed.ncbi.nlm.nih.gov/41764152/). *J Mol Med (Berl)*. [Basic Science / Preclinical]
Lindstedt S (2026). [PMID: 41045179](https://pubmed.ncbi.nlm.nih.gov/41045179/). *J Intellect Disabil Res*. [Review / Meta-Analysis]
Harripaul R (2026). [PMID: 41865132](https://pubmed.ncbi.nlm.nih.gov/41865132/). *Sci Rep*. [Basic Science / Preclinical]